![Ashley Arthur Woodcock](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ashley Arthur Woodcock
Oprichter bij Reacta Biotech Ltd.
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Clare Mills | F | - |
Reacta Biotech Ltd.
![]() Reacta Biotech Ltd. Miscellaneous Commercial ServicesCommercial Services Reacta Biotech Ltd. engages in a biotechnology company. It develops, manufactures, and commercializes oral food challenge materials to pharmaceuticals standards of Good Manufacturing Practice (GMP). The company was founded by Clare Mills, Ashley Woodcock, and Peter McPartland in June 2013 and is headquartered in Deeside, the United Kingdom. | 11 jaar |
Paul Glyer | M | - |
Axalbion Therapeutics Ltd.
![]() Axalbion Therapeutics Ltd. BiotechnologyHealth Technology Axalbion Therapeutics Ltd. has developed a drug candidate for several therapeutic applications. The private company is based in Wythenshawe, UK. The British company has evaluated new patented TRPM8 agonists, which are molecular transducers expressed in sensory neurons. The TRPM8 ion channel is expressed by approximately 10-15% of somatosensory neurons. Axalbion Therapeutics focuses on treating dry eye syndrome (DES), which is a disorder of the tear film due to tear deficiency. The company was founded in 2021, and the CEO is Michael M. Kitt.
Axalbion SA
| 7 jaar |
Adrian Field | M | - |
Axalbion Therapeutics Ltd.
![]() Axalbion Therapeutics Ltd. BiotechnologyHealth Technology Axalbion Therapeutics Ltd. has developed a drug candidate for several therapeutic applications. The private company is based in Wythenshawe, UK. The British company has evaluated new patented TRPM8 agonists, which are molecular transducers expressed in sensory neurons. The TRPM8 ion channel is expressed by approximately 10-15% of somatosensory neurons. Axalbion Therapeutics focuses on treating dry eye syndrome (DES), which is a disorder of the tear film due to tear deficiency. The company was founded in 2021, and the CEO is Michael M. Kitt.
Axalbion SA
| - |
Peter Vitins | M | - |
Axalbion Therapeutics Ltd.
![]() Axalbion Therapeutics Ltd. BiotechnologyHealth Technology Axalbion Therapeutics Ltd. has developed a drug candidate for several therapeutic applications. The private company is based in Wythenshawe, UK. The British company has evaluated new patented TRPM8 agonists, which are molecular transducers expressed in sensory neurons. The TRPM8 ion channel is expressed by approximately 10-15% of somatosensory neurons. Axalbion Therapeutics focuses on treating dry eye syndrome (DES), which is a disorder of the tear film due to tear deficiency. The company was founded in 2021, and the CEO is Michael M. Kitt.
Axalbion SA
| - |
Peter McPartland | M | 70 |
Reacta Biotech Ltd.
![]() Reacta Biotech Ltd. Miscellaneous Commercial ServicesCommercial Services Reacta Biotech Ltd. engages in a biotechnology company. It develops, manufactures, and commercializes oral food challenge materials to pharmaceuticals standards of Good Manufacturing Practice (GMP). The company was founded by Clare Mills, Ashley Woodcock, and Peter McPartland in June 2013 and is headquartered in Deeside, the United Kingdom. | 11 jaar |
Marc Henry Rochat | M | - |
Axalbion Therapeutics Ltd.
![]() Axalbion Therapeutics Ltd. BiotechnologyHealth Technology Axalbion Therapeutics Ltd. has developed a drug candidate for several therapeutic applications. The private company is based in Wythenshawe, UK. The British company has evaluated new patented TRPM8 agonists, which are molecular transducers expressed in sensory neurons. The TRPM8 ion channel is expressed by approximately 10-15% of somatosensory neurons. Axalbion Therapeutics focuses on treating dry eye syndrome (DES), which is a disorder of the tear film due to tear deficiency. The company was founded in 2021, and the CEO is Michael M. Kitt.
Axalbion SA
| - |
Mark Andrew Woodhead | M | - |
North West Lung Centre
![]() North West Lung Centre Medical/Nursing ServicesHealth Services North West Lung Centre provides services related to other human health activities. | - |
Michael Kitt | M | - |
Axalbion SA
| - |
Andrew Mark Jones | M | - |
North West Lung Centre
![]() North West Lung Centre Medical/Nursing ServicesHealth Services North West Lung Centre provides services related to other human health activities. | - |
Paul Glyer | M | 67 |
Axalbion SA
| - |
Yvonne Jane Summers | M | - |
North West Lung Centre
![]() North West Lung Centre Medical/Nursing ServicesHealth Services North West Lung Centre provides services related to other human health activities. | - |
Michael M. Kitt | M | 73 |
Axalbion Therapeutics Ltd.
![]() Axalbion Therapeutics Ltd. BiotechnologyHealth Technology Axalbion Therapeutics Ltd. has developed a drug candidate for several therapeutic applications. The private company is based in Wythenshawe, UK. The British company has evaluated new patented TRPM8 agonists, which are molecular transducers expressed in sensory neurons. The TRPM8 ion channel is expressed by approximately 10-15% of somatosensory neurons. Axalbion Therapeutics focuses on treating dry eye syndrome (DES), which is a disorder of the tear film due to tear deficiency. The company was founded in 2021, and the CEO is Michael M. Kitt. | - |
Clare Suzanne Murray | M | - |
North West Lung Centre
![]() North West Lung Centre Medical/Nursing ServicesHealth Services North West Lung Centre provides services related to other human health activities. | - |
John Herbert Alcock | M | - |
North West Lung Centre
![]() North West Lung Centre Medical/Nursing ServicesHealth Services North West Lung Centre provides services related to other human health activities. | - |
Anthony Kevin Webb | M | 78 |
North West Lung Centre
![]() North West Lung Centre Medical/Nursing ServicesHealth Services North West Lung Centre provides services related to other human health activities. | - |
Charles Anthony Cary Pickering | M | - |
North West Lung Centre
![]() North West Lung Centre Medical/Nursing ServicesHealth Services North West Lung Centre provides services related to other human health activities. | - |
Norman Molyneux | M | 68 |
Reacta Biotech Ltd.
![]() Reacta Biotech Ltd. Miscellaneous Commercial ServicesCommercial Services Reacta Biotech Ltd. engages in a biotechnology company. It develops, manufactures, and commercializes oral food challenge materials to pharmaceuticals standards of Good Manufacturing Practice (GMP). The company was founded by Clare Mills, Ashley Woodcock, and Peter McPartland in June 2013 and is headquartered in Deeside, the United Kingdom. | - |
Angela Simpson | M | - |
North West Lung Centre
![]() North West Lung Centre Medical/Nursing ServicesHealth Services North West Lung Centre provides services related to other human health activities. | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Brett K. Haumann | M | 54 |
Reacta Biotech Ltd.
![]() Reacta Biotech Ltd. Miscellaneous Commercial ServicesCommercial Services Reacta Biotech Ltd. engages in a biotechnology company. It develops, manufactures, and commercializes oral food challenge materials to pharmaceuticals standards of Good Manufacturing Practice (GMP). The company was founded by Clare Mills, Ashley Woodcock, and Peter McPartland in June 2013 and is headquartered in Deeside, the United Kingdom. | 2 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigd Koninkrijk | 17 | 89.47% |
Zwitserland | 6 | 31.58% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Ashley Arthur Woodcock
- Persoonlijk netwerk